Amelioration of postmenopausal primary hyperparathyroidism during adjuvant tamoxifen for breast cancer
- 1 November 1989
- Vol. 64 (9), 1965-1967
- https://doi.org/10.1002/1097-0142(19891101)64:9<1965::aid-cncr2820640933>3.0.co;2-g
Abstract
The effects of adjuvant treatment with tamoxifen on bone metabolism in a postmenopausal woman with primary hyperparathyroidism is presented. A 69‐year‐old woman with increased serum ionized calcium, parathyroid hormone, and 1,25‐(OH)2 vitamin D levels and a normal bone scan received tamoxifen 10 mg three times daily for 1 year. During treatment bone turnover decreased whereas parathyroid hormone increased further. After cessation of treatment the calcium metabolic variables returned to pretreatment levels. The antiestrogen tamoxifen seems to behave as an estrogen on bone metabolism in primary hyperparathyroidism.This publication has 17 references indexed in Scilit:
- Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two yearsBreast Cancer Research and Treatment, 1988
- Tamoxifen Inhibits Osteoclast-Mediated Resorption of Trabecular Bone in Ovarian Hormone-Deficient Rats*Endocrinology, 1988
- Effects of anti-estrogens on bone in castrated and intact female ratsBreast Cancer Research and Treatment, 1987
- Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in ratsJournal of Bone and Mineral Research, 1987
- Ethinyl Estradiol and Norethindrone in the Treatment of Primary Hyperparathyroidism in Postmenopausal WomenNew England Journal of Medicine, 1986
- Effects of the Antiestrogens Tamoxifen and Clomiphene on Bone Resorptionin Vitro*Endocrinology, 1986
- The effect of tamoxifen on bone mineral content in premenopausal women with breast cancerCancer, 1984
- Asymptomatic hypercalcemia and primary hyperparathyroidismPublished by Elsevier ,1982
- Seasonal Changes in the Activity of Serum Alkaline PhosphataseEnzyme, 1981
- Malignant neoplasms and parathyroid adenomaCancer, 1971